Addictions in pain clinics and pain treatment

Annals of the New York Academy of Sciences

Volumn 1216, Issue 1, 2011, Pages 138-143

  Passik, Steven D ^a   Kirsh, Kenneth L ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b The Pain Treatment Center of the Bluegrass   (United States)

Author keywords

Addiction; Management; Pain

Indexed keywords

OPIATE;

ARTICLE; AWARENESS; DRUG ABUSE; DRUG DEPENDENCE; HEALTH CARE PERSONNEL; HUMAN; PAIN CLINIC;

EID: 79251472413     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05897.x     Document Type: Article

References (42)

1. Manchikanti, L. 2006. Prescription drug abuse: what is being done to address this new drug epidemic? Testimony before the Subcommittee on Criminal Justice, Drug Policy and Human Resources. Pain Physician 9: 287-321.
2. National Center on Addiction and Substance Abuse. 2006. Controlled prescription drug abuse at epidemic level. J. Pain Palliat. Care Pharmacother. 20: 61-64.
3. Passik, S.D., H. Heit & K.L. Kirsh 2006. Reality and responsibility: a commentary on the treatment of pain and suffering in a drug-using society. J. Opioid. Manage. 2: 123-127.
4. Hertz, J.A. & J.R. Knight 2006. Prescription drug misuse: a growing national problem. Adolesc. Med. Clin. 17: 751-769.
5. McCarberg, B.H. & R. Billington 2006. Consequences of neuropathic pain: quality-of-life issues and associated costs. Am. J. Manag. Care. 12(9 Suppl): S263-S268.
6. Passik, SD. 2009. Issues in long-term opioid therapy: unmet needs, risks, and solutions. Mayo. Clin. Proc. 84: 593-601.
7. Wunsch, M.J., K.L. Cropsey, E.D. Campbell & J.S. Knisely 2008. Oxycontin use and misuse in three populations: substance abuse patients, pain patients, and criminal justice participants. J. Opioid. Manage. 4: 73-79.
8. Wysowski, D.K. 2007. Surveillance of prescription drug-related mortality using death certificate data. Drug Saf. 30: 533-540.
9. US General Accounting Office. Prescription drugs: oxycontin abuse and diversion and efforts to address the problem (GAO-04-110). USGPO; 2003 [Dec 2009]., accessed January 10, 2010.
10. U.S. House of Representatives. Hearing before the Subcommittee on Crime of the Committee on the Judiciary, House of Representatives, 106th Congress, July 29, 1999. 2000.
11. Office of National Drug Control Policy. Press Release: White House Department of Justice release first-ever comprehensive Hational Action Plan to reduce synthetic drug production, trafficking, and abuse: plan focuses on methamphetamine, prescription drugs, and club drugs. Office of National Drug Control Policy. 2004.
12. Rannazzisi JT. Statement of Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, on the National Synthetic Drug Control Strategy, given in testimony before the House Government Reform Committee, Subcommittee on Criminal Justice, Drug Policy and Human Resources. 2006., accessed January 10, 2010.
13. U.S. House Committee on Government Reform. 2005. Statement of Robert J. Meyer, M.D., Director, Office of Drug Evaluation II, Center for Drug Evaluation and Research, Food and Drug Administration: FDA's role in preventing prescription drug abuse. House Committee on Government Reform, U.S. House of Representatives (September 13, 2005).
14. AMDG. Washington Agency Medical Directors Group. Interagency guideline on opioid dosing for chronic non-cancer pain: an educational aid to improve care and safety with opioid therapy, 2010 update. Accessed October 10, 2010.
15. Cicero, T.J., J.A. Inciardi & A. Munoz 2005. Trends in abuse of OxyContin and other opioid analgesics in the United States: 2002-2004. J. Pain 6: 662-672.
16. Lipman, A.G. 2005. Does the DEA truly seek balance in pain medicine? J. Pain Palliat. Care Pharmacother.19: 7-9.
17. Passik SD & Kirsh KL. 2007. King of pain: what Elvis' death tells us about media coverage of celebrities and the pain. J. Opioid. Manage. 3: 69-70.
18. Passik SD & Kirsh KL. 2009. Death of two kings. Pain Med. News 7: 6-7.
19. Rinaldi, R.C., E.M. Steindler, B.B. Wilford & D. Goodwin 1988. Clarification and standardization of substance abuse terminology. J. Amer. Med. Assoc. 259: 555.
20. Weissman, D.E. & J.D. Haddox 1989. Opioid pseudoaddiction: an iatrogenic syndrome. Pain 36: 363-366.
21. Passik, S.D. & R.K. Portenoy 1998. Substance abuse issues in palliative care. In Principles and Practice of Supportive Oncology. A. Berger, et al., Ed.: 513-524. Lippincott-Raven Publishers, Philadelphia PA
22. Passik, S.D., R.K. Portenoy & P.L. Ricketts 1998. Substance abuse issues in cancer patients part 1: prevalence and diagnosis. Oncology 12: 517-521.
23. Dole, V.P. 1972. Narcotic addiction, physical dependence and relapse. N. Engl. J. Med. 286: 988-991.
24. Martin, W.R. & D.R. Jasinski 1969. Physiological parameters of morphine dependence in man-tolerance, early abstinence, protracted abstinence. J. Psychiatr. Res. 7: 9-13.
25. Candiotti, K.A. & M.C. Gitlin 2010. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution? Curr. Med. Res. Opin. 26: 1677-1684.
26. Noble, M, J.R. Treadwell, S.J. Tregear, et al 2010. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst. Rev. 20: CD006605.
27. Butler, S.F., S.H. Budman, K. Fernandez & R.N. Jamison 2004. Validation of a screener and opioid assessment measure for patients with chronic pain. Pain 112: 65-75.
28. Webster, L.R. & R.M. Webster 2005. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool. Pain Med. 6: 432-442.
29. Chabal, C., M.K. Erjavec, L. Jacobson, et al 1997. Prescription opiate abuse in chronic pain patients: clinical criteria, incidence, and predictors. Clin. J. Pain. 13: 150-155.
30. Coambs, R.B. & J.L. Jarry 1996. The SISAP: a new screening instrument for identifying potential opioid abusers in the management of chronic nonmalignant pain in general medical practice. Pain. Res. Manage. 1: 15-162.
31. Crowe, R.R., J.R. Kramer, V. Hesselbrock, et al 1997. The utility of the 'Brief MAST' and the 'CAGE' in identifying alcohol problems. Arch. Fam. Med. 6: 477-483.
32. Gavin, D.R., H.E. Ross & H.A. Skinner 1989. Diagnostic validity of the drug abuse screening test in the assessment of DSM-III drug disorders. Br. J. Addict. 84: 301-307.
33. Hinkin, C.H., S.A. Castellon, E. Dickson-Fuhrman, et al 2001. Screening for drug and alcohol abuse among older adults using a modified version of the CAGE. Am. J. Addict. 10: 319-326.
34. Leonardson, G.R., E. Kemper, F.K. Ness, et al 2005. Validity and reliability of the audit and CAGE-AID in Northern Plains American Indians. Psychol. Rep. 97: 161-166.
35. Skinner, H.A. 1982. The drug abuse screening test. Addict. Behav. 7: 363-371.
36. Passik, S.D. & H.J. Weinreb 2000. Managing chronic nonmalignant pain: overcoming obstacles to the use of opioids. Adv. Therapy 17: 70-80.
37. Passik, S.D. & K.L. Kirsh 2004. A new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapy. Clin. Therap. 26: 552-561.
38. Passik, S.D., K.L. Kirsh, L.A. Whitcomb, et al 2005. Monitoring outcomes during long-term opioid therapy for non-cancer pain: results with the pain assessment and documentation tool. J. Opioid. Manage. 1: 257-266.
39. Passik, S.D., R.K. Portenoy & P.L. Ricketts 1998. Substance abuse issues in cancer patients. Part 2: evaluation and treatment. Oncology 12: 729-734.
40. Parrino M. State Methadone Treatment Guidelines. TIPS 1 DHHS Publication No. (SMA) 93-1991. SMA. Washington, D.C
41. Passik, S., J. Schreiber & K.L. Kirsh 2000. A chart review of the ordering and documentation of urine toxicology screens in a cancer center: do they influence patient management? J. Pain. Symptom. Manage. 19: 40-44.
42. Passik, S.D. & K.L. Kirsh 2008. The interface between pain and drug abuse and the evolution of strategies to optimize pain management while minimizing drug abuse. Exp. Clin. Psychopharmacol. 16: 400-404.